EUVIMEDEUVIMED entdecken
Editorial

Editorial Comment to Real‐World Occurrence of Adverse Events Associated With Adjuvant Pembrolizumab Therapy for Renal Cell Carcinoma: A Multicenter Retrospective Study

Hajime Tanaka iD

International Journal of Urology · 2026-06 · 33 (6)

DOI: 10.1111/iju.70545 ↗

Kurz gefasst

Editorial in der Zeitschrift International Journal of Urology, online erschienen am 19.06.2026. Verfasst von Hajime Tanaka. Beteiligte Einrichtung: Department of Urology, Institute of Science Tokyo, Tokyo, Japan. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 5 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Department of Urology, Institute of Science Tokyo, Tokyo, Japan.

ORCID-Profile: Hajime Tanaka

Zitieren

APA

Tanaka, H. (2026). Editorial Comment to Real‐World Occurrence of Adverse Events Associated With Adjuvant Pembrolizumab Therapy for Renal Cell Carcinoma: A Multicenter Retrospective Study. International Journal of Urology, 33(6). https://doi.org/10.1111/iju.70545

Vancouver

Tanaka H. Editorial Comment to Real‐World Occurrence of Adverse Events Associated With Adjuvant Pembrolizumab Therapy for Renal Cell Carcinoma: A Multicenter Retrospective Study. International Journal of Urology. 2026;33(6). doi:10.1111/iju.70545

BibTeX
@article{Tanaka2026,
  author = {Tanaka, Hajime},
  title = {Editorial Comment to Real‐World Occurrence of Adverse Events Associated With Adjuvant Pembrolizumab Therapy for Renal Cell Carcinoma: A Multicenter Retrospective Study},
  journal = {International Journal of Urology},
  year = {2026},
  volume = {33},
  number = {6},
  doi = {10.1111/iju.70545}
}
Kostenlos starten →